<?xml version="1.0" encoding="UTF-8"?>
<ref id="B69-biomedicines-08-00060">
 <label>69.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yin</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Han</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Zhen</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Xiao</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Sun</surname>
    <given-names>Y.</given-names>
   </name>
  </person-group>
  <article-title>Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo</article-title>
  <source>Ther. Clin. Risk Manag.</source>
  <year>2017</year>
  <volume>13</volume>
  <fpage>117</fpage>
  <lpage>130</lpage>
  <pub-id pub-id-type="doi">10.2147/TCRM.S128575</pub-id>
  <pub-id pub-id-type="pmid">28223815</pub-id>
 </element-citation>
</ref>
